Austria-based OncoOne launched with a Series A financing round worth 13 million euros ($14.26 million).

New York City-based HiberCell launched with a $60.75 million Series A funding, led by ARCH Venture Partners.

Locus Biosciences inked a collaboration and license deal with J&J’s Janssen Pharmaceutical to develop precision antibacterial therapies based on CRISPR-Cas3-enhanced bacteriophage.

Boehringer Ingelheim exercised an option to buy an EMBL Ventures portfolio company, ViraTherapeutics.

Cambridge, Mass.-based Twentyeight-Seven Therapeutics (28-7) completed a $65 million Series A financing.

Expansion Therapeutics officially launched with the close of a $55.3 million Series A financing.